Barclays lowered the firm’s price target on PacBio to $3 from $8 and keeps an Equal Weight rating on the shares. The analyst says Q1 is shaping up to be a rather inconsequential “do nothing” quarter for the life science tools and diagnostics space. The firm does not expect to get a lot of data one way or the other on many of the bull/bear debates. It believes investors continue to favor bioprocessing names broadly over instrument-focused companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- Cathie Wood’s ARK Investment bought 190K shares of PacBio today
- Cathie Wood’s ARK Investment bought 273K shares of PacBio today
- PacBio’s Revio HiFi sequencing system selected by University of Tartu
- PacBio price target lowered to $10 from $14 at Canaccord
- Pac Bio call volume above normal and directionally bullish
